0000921895-20-000159.txt : 20200123 0000921895-20-000159.hdr.sgml : 20200123 20200123143325 ACCESSION NUMBER: 0000921895-20-000159 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20200123 DATE AS OF CHANGE: 20200123 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics plc CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-88759 FILM NUMBER: 20541562 BUSINESS ADDRESS: STREET 1: 136A EASTERN AVENUE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4SB BUSINESS PHONE: 44-123-544-3939 MAIL ADDRESS: STREET 1: 136A EASTERN AVENUE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4SB FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Zanganeh Maky CENTRAL INDEX KEY: 0001507650 FILING VALUES: FORM TYPE: SC 13D MAIL ADDRESS: STREET 1: MAKY ZANGANEH & ASSOCIATES STREET 2: 2087 SHARON ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 SC 13D 1 sc13d11732sum_01232020.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No.  )1

Summit Therapeutics, PLC

(Name of Issuer)

American Depositary Shares and Ordinary Shares, par value £0.01 per share

(Title of Class of Securities)

86627R102

(CUSIP Number)

ADAM W. FINERMAN, ESQ.

OLSHAN FROME WOLOSKY LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

January 14, 2020

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

 

 

 

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 86627R102

  1   NAME OF REPORTING PERSON  
         
        MAHKAM ZANGANEH  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
           
  4   SOURCE OF FUNDS  
         
        AF  
  5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
       
           
  6   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        U.S.A.  
NUMBER OF   7   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   8   SHARED VOTING POWER  
EACH          
REPORTING         24,202,220*  
PERSON WITH   9   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    10   SHARED DISPOSITIVE POWER  
           
          24,202,220*  
  11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        24,202,220*  
  12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
       
           
  13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
        7.14%*  
  14   TYPE OF REPORTING PERSON  
         
        IN  

 

* The 24,202,220 Ordinary Shares beneficially owned consist of 21,045,410 Ordinary Shares and includes the exercise of warrants to purchase 3,156,810 Ordinary Shares, which are first exercisable on June 24, 2020. Such Ordinary Shares and warrants are held by the Mahkam Zanganeh Revocable Trust and the Shaun Zanganeh Irrevocable Trust.

2

CUSIP No. 86627R102

  1   NAME OF REPORTING PERSON  
         
        MAHKAM ZANGANEH REVOCABLE TRUST  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
        (b) ☐
           
  3   SEC USE ONLY    
           
           
  4   SOURCE OF FUNDS  
         
        WC  
  5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
       
           
  6   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        CALIFORNIA  
NUMBER OF   7   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   8   SHARED VOTING POWER  
EACH          
REPORTING         12,101,110*  
PERSON WITH   9   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    10   SHARED DISPOSITIVE POWER  
           
          12,101,110*  
  11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        12,101,110*  
  12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
       
           
  13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
        3.59%*  
  14   TYPE OF REPORTING PERSON  
         
        OO  

 

* The 12,101,110 Ordinary Shares beneficially owned consist of 10,522,705 Ordinary Shares and includes the exercise of warrants to purchase 1,578,405 Ordinary Shares, which are first exercisable on June 24, 2020.

3

CUSIP No. 86627R102

 

  1   NAME OF REPORTING PERSON  
         
        SHAUN ZANGANEH IRREVOCABLE TRUST  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐☒
        (b) ☐
           
  3   SEC USE ONLY    
           
           
  4   SOURCE OF FUNDS  
         
        WC  
  5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
       
           
  6   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        CALIFORNIA  
NUMBER OF   7   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   8   SHARED VOTING POWER  
EACH          
REPORTING         12,101,110*  
PERSON WITH   9   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    10   SHARED DISPOSITIVE POWER  
           
          12,101,110*  
  11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        12,101,110*  
  12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
       
           
  13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
        3.59%*  
  14   TYPE OF REPORTING PERSON  
         
        OO  

  

* The 12,101,110 Ordinary Shares beneficially owned consist of 10,522,705 Ordinary Shares and includes the exercise of warrants to purchase 1,578,405 Ordinary Shares, which are first exercisable on June 24, 2020.

4

CUSIP No. 86627R102

The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”).

Item 1.Security and Issuer.

This statement on Schedule 13D relates to the Ordinary Shares, par value £0.01 per share (the “Ordinary Shares”), of Summit Therapeutics PLC, a foreign private issuer incorporated in England and Wales whose principal executive office is located at 136A Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, United Kingdom (the “Issuer”).

Item 2.Identity and Background.
(a)This statement is filed by:
i.Mahkam Zanganeh;
ii.Mahkam Zanganeh Revocable Trust (“Trust I”);
iii.Shaun Zanganeh Irrevocable Trust (“Trust II” and collectively with Trust I, the “Trusts”);

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to the Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

(b)The principal business address of each Reporting Person is 51 Adam Way, Atherton, California 94027.
(c)The principal occupation of Ms. Zanganeh is serving as Chief Executive Officer of Maky Zanganeh & Associates, Inc., a consultancy firm. The principle business of each Trust is to hold and invest securities and other assets as a fiduciary for the benefit of each of their respective beneficiaries.
(d)No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)Ms. Zanganeh is a citizen of the United States of America. Each Trust is organized under the laws of the state of California.
Item 3.Source and Amount of Funds or Other Consideration.

The Ordinary Shares owned by the Trusts were purchased with working capital pursuant to a Stock Purchase Agreement, dated December 24, 2019, by and among Robert Duggan, Trust I and Trust II (the “SPA”), which closed on January 14, 2020. The aggregate purchase price for the purchase of the 21,045,410 Ordinary Shares and warrants to purchase an additional 3,156,810 Ordinary Shares owned by the Trusts is approximately $5,999,999.

5

CUSIP No. 86627R102

Item 4.Purpose of Transaction.

The Trusts purchased the Ordinary Shares based on each Reporting Person’s belief that the Ordinary Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Ordinary Shares at prices that would make the purchase or sale of Ordinary Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Ordinary Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

On January 14, 2020, each Trust acquired (i) 10,522,705 Ordinary Shares and (ii) warrants to purchase 1,578,405 Ordinary Shares. The Ordinary Shares and warrants were acquired pursuant to the SPA, in accordance with the right of the seller thereunder to substitute Ordinary Shares and warrants for the Issuer’s American Depositary Shares (each representing five Ordinary Shares) pursuant to Section 1.07 of the SPA. The warrants described in clause (ii) above are fully vested, and are exercisable at any time during the period beginning on June 24, 2020 and ending on December 24, 2029. Such warrants are governed by the terms of that certain Warrant Instrument, dated as of December 6, 2019 (the “Warrant Instrument”). The SPA and the Warrant Instrument are attached hereto as Exhibits 99.1 and 99.2 respectively. The foregoing description of the SPA and the Warrant Instrument does not purport to be complete and is qualified in its entirety by reference to the full text of the SPA and the Warrant Instrument, each of which is incorporated by reference herein.

The Reporting Persons do not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position, each Trusts’ investment strategy, the price levels of the Ordinary Shares, conditions in the securities markets and general economic and industry conditions and the terms and conditions of the Warrant Instrument (as hereinafter defined), the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as deemed appropriate including, without limitation, engaging in additional communications with management and the Board, engaging in discussions with stockholders of the Issuer and others about the Issuer and each Reporting Person’s investment, making proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition) or operations of the Issuer, purchasing additional Ordinary Shares, selling some or all of their Ordinary Shares, engaging in short selling of or any hedging or similar transaction with respect to the Ordinary Shares, or changing their intentions with respect to any and all matters referred to in Item 4.

Item 5.Interest in Securities of the Issuer.
(a)The aggregate percentage of Ordinary Shares reported owned by the Reporting Persons is based on the Issuer’s calculation that it has 335,873,208 Ordinary Shares outstanding as of January 14, 2020. As of the close of business on January 14, 2020, through the holding of 10,522,705 Ordinary Shares and warrants to purchase 1,578,405 Ordinary Shares, each Trust beneficially owned approximately 3.59% of the Ordinary Shares outstanding. Ms. Zanganeh, as sole trustee of each Trust, may be deemed to beneficially own the 21,045,410 Ordinary Shares and warrants to purchase an additional 3,156,810 Ordinary Shares held in the aggregate by the Trusts. Based on the foregoing, Ms. Zanganeh’s beneficial ownership would constitute approximately 7.14% of the Ordinary Shares outstanding.
6

CUSIP No. 86627R102

(b)By virtue of Ms. Zanganeh’s position as the sole trustee of each Trust, she may be deemed to have the shared power to vote and direct the disposition of 24,202,220 Ordinary Shares in the aggregate (including the warrants disclosed herein on an as-exercised basis). Each Trust may be deemed to have the shared power to vote and direct the disposition of 12,101,110 Ordinary Shares in the aggregate (including the warrants disclosed herein on an as-exercised basis).
(c)The transactions in the Ordinary Shares by the Reporting Persons during the past sixty days are set forth in Schedule A and are incorporated herein by reference.
(d)No person, other than the Reporting Persons, is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares.
(e)Not applicable.
Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

On December 6, 2019, the Issuer entered into a Consulting Agreement (the “Consulting Agreement”) with Maky Zanganeh & Associates, Inc. (“MZA”), a consulting company controlled by Ms. Zanganeh. Pursuant to the Consulting Agreement, MZA is entitled to receive warrants to purchase Ordinary Shares. The warrants issued under the Consulting Agreement vest quarterly over the period beginning on December 24, 2019 and ending on December 24, 2022 in accordance with the terms of that certain Consultant Warrant Agreement, dated December 6, 2019 by and between the Issuer and MZA (the “Consultant Warrant Agreement”). The first tranche is expected to vest and become exercisable on March 24, 2020 subject to the terms of the Consulting Agreement and the Consultant Warrant Agreement. No warrants issued pursuant to the Consultant Warrant Agreement are currently vested as of the date of filing this Schedule 13D, and accordingly no such warrants have been factored into the calculations of beneficial ownership set forth herein.

The foregoing description of the Consulting Agreement and the Consultant Warrant Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement and Consultant Warrant Agreement, included as Exhibits 99.3 and 99.4 hereto and incorporated by reference herein.

On January 23, 2020, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D, with respect to securities of the Issuer, to the extent required by applicable law. A copy of this agreement is attached hereto as Exhibit 99.5 and is incorporated herein by reference.

Other than as described herein, there are no contracts, arrangements, understandings or relationships between the Reporting Persons and any other person, with respect to the securities of the Issuer.

7

CUSIP No. 86627R102

Item 7.Material to be Filed as Exhibits.
99.1*Stock Purchase Agreement, dated December 24, 2019, by and among Robert Duggan, Trust I and Trust II.
99.2Warrant Instrument, dated December 6, 2019 (incorporated by reference to Exhibit 2.1 of the Issuer’s Form 6-K filed on December 6, 2019).
99.3Consulting Agreement, dated December 6, 2019, by and between the Issuer and MZA (incorporated by reference to Exhibit 4.4 of the Issuer’s Form 6-K filed on December 6, 2019).
99.4Consultant Warrant Agreement, dated December 6, 2019, by and between the Issuer and MZA (incorporated by reference to Exhibit 2.2 of the Issuer’s Form 6-K filed on December 6, 2019).
99.5*Joint Filing Agreement, dated January 23, 2020, by and among Mahkam Zanganeh, Trust I and Trust II.

* Filed herewith.

8

CUSIP No. 86627R102

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 23, 2020

 

 

/s/ Mahkam Zanganeh

  Mahkam Zanganeh
   
   
  MAHKAM ZANGANEH REVOCABLE TRUST
  SHAUN ZANGANEH IRREVOCABLE TRUST
   
  By:

/s/ Mahkam Zanganeh

    Name: Mahkam Zanganeh
    Title: Trustee

 

9

CUSIP No. 86627R102

SCHEDULE A

Transactions in the Ordinary Shares During the Past Sixty Days

Type of Security Securities
Purchased / (Sold)
Price Per
Share(£)
Date of
Purchase / Sale
       
MAHKAM ZANGANEH REVOCABLE TRUST
       
Ordinary Shares 10,522,705 £0.221 1/14/20
Warrants* 1,578,405   1/14/20
       
SHAUN ZANGANEH IRREVOCABLE TRUST
       
Ordinary Shares 10,522,705 £0.221 1/14/20
Warrants* 1,578,405   1/14/20

 

* Represents Ordinary Shares issuable upon exercise of the warrants purchased pursuant to the SPA and governed by the Warrant Instrument. Such warrants are exercisable from June 24, 2020 to December 24, 2029 at a price of £0.243 per Ordinary Share.

EX-99.1 2 ex991to13d11732sum_01232020.htm

Exhibit 99.1

 

STOCK PURCHASE AGREEMENT

This Stock Purchase (this “Agreement”) is dated as of December 24, 2019, and entered into between Robert Duggan, an individual (the “Seller”) and each of the parties listed on Exhibit A hereto (each such party, a “Buyer”, and each of the Buyers and the Seller, a “Party” to this Agreement, and collectively, the “Parties”) for the purchase of certain equity interests of Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales (the “Company”).

As of the date hereof and pursuant to the closing of that certain Securities Purchase Agreement (“SPA”) by and between the Company and the Seller, the Seller beneficially owns 166,157,050 ordinary shares, par value £0.01 per share of the Company (the “Ordinary Shares”) and warrants to purchase an aggregate of 24,923,555 Ordinary Shares (the “Warrants”). In addition, the Seller owns 15,657,641 American Depository Shares (the “ADS Shares”), which may be exchanged for Ordinary Shares at a 1:5 ratio.

The Parties hereby agree as follows:

ArticleI.                   PURCHASE AND SALE OF STOCK

Section 1.01        Sale of Shares. On the terms and subject to the conditions set forth in this Agreement, the Seller agrees to sell, assign, transfer and deliver to each Buyer at the Closing, and each Buyer agrees to purchase and redeem from the Seller at the Closing, ADS Shares held by the Seller in the amount set forth opposite each Buyer’s name in Exhibit A (the “Shares”).

Section 1.02        Purchase Price. Each Buyer will purchase their respective Shares for an aggregate purchase price as set forth opposite each Buyer’s name on Exhibit A (each such aggregate price, the “Purchase Price”).

Section 1.03        Closing. Subject to the satisfaction or waiver of the conditions to closing of this Agreement, the closing of the transactions contemplated hereby (the “Closing”) will take place on January 10, 2020, or at such other time as may be agreed in writing by the Seller and each respective Buyer with respect to such Buyer (the “Closing Date”) upon satisfactory delivery of the Shares to each Buyer and payment to the Seller of the Purchase Price by wire transfer of immediately available funds to the account(s) designated via email by the Seller. Delivery of the Shares shall be made by electronic delivery to each Buyer of the Shares held in street name and purchased from the Seller pursuant hereto through the Depository Trust Company to an account maintained by the Company’s transfer agent for the benefit of the Company and, with respect to Shares held of record, by delivery of a certificate or certificates representing such Shares duly endorsed for transfer or accompanied by appropriate stock powers duly executed in blank and other appropriate instructions to the Company’s transfer agent. In either case, the Parties mutually agree to execute and deliver any other documents as are reasonably required by the Company’s transfer agent to consummate the Closing.

Section 1.04        Conditions to Closing.

(a)Conditions to Obligations of Seller.
 

 

(i)Each Buyer shall have taken all such action and signed any documents required to effect the acceptance by Buyer of any obligations that will be binding on Buyer as a holder of the Shares upon the Closing.
(ii)No order, injunction, statute, rule, regulation or decree shall have been issued, enacted, entered, promulgated or enforced by a governmental entity that prohibits, restrains, enjoins or makes illegal the consummation of the transactions contemplated by this Agreement.
(iii)The representations and warranties of each Buyer set forth in this Agreement shall be true and correct in all respects as of the date of this Agreement (except to the extent such representations and warranties speak as of an earlier date) and as of the Closing Date as though made on and as of the Closing Date.

 

(b)Conditions to Obligations of each Buyer.
(i)No order, injunction, statute, rule, regulation or decree shall have been issued, enacted, entered, promulgated or enforced by a governmental entity that prohibits, restrains, enjoins or makes illegal the consummation of the transactions contemplated by this Agreement.
(ii)The representations and warranties of the Seller set forth in this Agreement shall be true and correct in all respects as of the date of this Agreement (except to the extent such representations and warranties speak as of an earlier date) and as of the Closing Date as though made on and as of the Closing Date.

Section 1.05        Representations and Warranties of the Seller. The Seller hereby makes the following representations and warranties to each Buyer, each of which is true and correct as of the date hereof and as of the Closing Date and each of which will survive the Closing and the transactions contemplated hereby:

(a)Ownership. The Seller is the sole direct beneficial owner of the Shares. The Shares are owned by the Seller, and will be transferred to each respective Buyer, free and clear of any and all liens, pledges, claims, encumbrances, security interests, rights of first refusal, options, conditions, restrictions, rights, interests or charges of any kind or character (except for those obligations of Seller to which each Buyer must accede in order to satisfy Section 1.04(a)(i) and consummate the Closing).
(b)Authority. The Seller has all requisite power and authority to execute, deliver and perform his obligations under this Agreement.
(c)Binding Obligations. This Agreement has been duly executed and delivered by the Seller and constitutes a legal, valid and binding obligation of the Seller.
(d)Consents. No governmental consent, approval, authorization, license or clearance, or filing or registration with any governmental or regulatory authority, is required in order to permit the Seller to perform his obligations under this Agreement, except for (i) such as have been obtained as of the Closing and (ii) an amendment to the Seller’s beneficial ownership report on Schedule 13D (the “13D Amendment”) filed with the Securities and Exchange Commission (the “SEC”) within the two business days following the Closing Date.

2

 

Section 1.06        Representations and Warranties of each Buyer. Each Buyer hereby makes the following representations and warranties to the Seller with respect to itself (and not on behalf of any other Buyer), each of which is true and correct as of the date hereof and as of the Closing Date and each of which will survive the Closing and the transactions contemplated hereby:

(a)Authority; Assets. Each Buyer has all requisite power and authority to execute, deliver and perform its obligations under this Agreement. Each Buyer has adequate assets to pay the Purchase Price.
(b)Binding Obligations. This Agreement has been duly executed and delivered by each Buyer and constitutes a legal, valid and binding obligation of each Buyer, enforceable against each Buyer in accordance with its terms.
(c)Consents. No governmental consent, approval, authorization, license or clearance, or filing or registration with any governmental or regulatory authority, is required in order to permit each Buyer to perform its obligations under this Agreement, except for such as have been obtained.
(d)Reliance. Each Buyer has made its own decision concerning the transactions contemplated by this Agreement without reliance on any representation or warranty of, or advice from, the Seller other than those set forth in Section 1.05. Each Buyer acknowledges and understands that the Seller possesses material nonpublic information regarding the Company not known to any Buyer that may impact the value of the Shares, including, without limitation, (x) information received from individuals in their capacities as directors, officers, significant stockholders or affiliates of the Company, (y) information otherwise received from the Company on a confidential basis, and (z) information received on a privileged basis from the attorneys and financial advisers representing the Company (collectively, the “Information”), and that the Seller is not disclosing the Information to any Buyer. Each Buyer understands, based on its experience, the disadvantage to which each Buyer is subject due to the disparity of information between the Seller and each Buyer. Notwithstanding such disparity, each Buyer has deemed it appropriate to enter into this Agreement and to consummate the transactions contemplated by this Agreement.
(e)Investment. Each Buyer is acquiring the Shares for its own account as principal, not as a nominee or agent, for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof in whole or in part and no other person or entity has a direct or indirect beneficial interest in the Shares. Each Buyer represents that it does not have any contract, undertaking, agreement or arrangement with any person or entity to sell, transfer or grant participations to any third party with respect to the Shares.
3

 

(f)Exemption From Registration. Each Buyer acknowledges that the Shares are intended to be exempt from registration under the Securities Act of 1933 (“Securities Act”) by virtue of Rule 506(b) of Regulation D under Section 4(a)(2) of the Securities Act. In furtherance thereof, each Buyer represents and warrants to the Seller that (i) it realizes that the basis for the exemption from registration under the Securities Act may not be present if it intends to acquire the Shares only for a fixed or determinable period of time, (ii) it has the financial ability to bear the economic risk of its investment in the Shares, has adequate means for providing for its current needs and contingencies and has no need for liquidity with respect to its investment in the Shares and (iii) it and its representatives (if applicable) has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Shares.
(g)Accredited Investor. Each Buyer has reviewed the definition of an “accredited investor,” as that term is defined in Rule 501(a) of Regulation D of the Securities Act, and each Buyer is an “accredited investor” as defined thereunder.

Section 1.07        Substitution. At the Closing, the Seller may, in his sole discretion, substitute (which shall be at a ratio of five (5) Ordinary Shares for each ADS Share, with such number of Purchased Warrants (as defined in the SPA) as included with each Ordinary Share pursuant to the SPA) any or all of the Shares to be sold hereunder with an equivalent proportion of Purchased Securities (as defined in the SPA) for the same Purchase Price. In the event of a substitution by Seller, (i) the Seller’s representations and warranties in Section 1.05 applicable to the Shares shall apply to any and all Purchased Securities substituted therefor, (ii) Seller shall notify Buyer prior to the Closing of the Purchased Securities being substituted and (iii) all references to “Shares” herein shall be deemed to include any substituted Purchased Securities, mutatis mutandis.

ArticleII.                MISCELLANEOUS

Section 2.01        Notices. All notices, requests and other communications to any Party hereunder will be in writing (including prepaid overnight courier) and will be given to such Party at its address or email address set forth on Exhibit A (or, in the case of Seller, on the signature page attached hereto), or at such other address or email address as such Party may hereafter specify in writing. Each such notice, request or other communication will be effective (a) if given by email, when transmitted to the email address specified in this Section and confirmation of receipt is received by the sender, (b) one business day after deposit with a reputable overnight courier properly addressed and with all charges prepaid or (c) when received, if by any other means. The Parties will promptly notify each other in the manner provided in this Section of any change in their respective addresses. A notice of change of address will not be deemed to have been given until received by the addressee.

Section 2.02        Expenses. Each Party shall bear its own expenses incurred in connection with the preparation of this Agreement.

4

 

Section 2.03        Specific Performance. Each of the Parties acknowledges and agrees that irreparable injury to the other Parties would occur if any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately compensable by the remedies available at law (including the payment of money damages). It is accordingly agreed that each individual Party herein will each be entitled to specific enforcement of, and injunctive relief to prevent any violation of, the terms hereof, and the other Parties will not take action, directly or indirectly, in opposition to the moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in equity. This Section 2.04 is not the exclusive remedy for any violation of this Agreement.

Section 2.04        Further Assurances. Each Party will execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions of this Agreement and give effect to the transactions contemplated by this Agreement.

Section 2.05        Assignment. No Party will assign this Agreement or any rights, interests or obligations hereunder, or delegate performance of any of its obligations hereunder, without the prior written consent of the other Parties.

Section 2.06        Entire Agreement. This Agreement constitutes the entire agreement and understanding of the Parties in respect of the subject matter contained herein. This Agreement supersedes all prior agreements and understandings between the Parties with respect to the subject matter hereof.

Section 2.07        Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement will remain in full force and effect and will not be affected, impaired or invalidated. In addition, the Parties agree to use commercially reasonable efforts to agree upon and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable by a court of competent jurisdiction.

Section 2.08        Waiver, Amendment, etc. This Agreement may not be amended or supplemented, and no waivers of or consents to or departures from the provisions hereof will be effective, unless set forth in a writing, and delivered to, the other applicable Parties. No failure or delay of any Party in exercising any power or right under this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any right or power, or any abandonment or discontinuance of steps to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power.

Section 2.09        Binding Agreement; No Third Party Beneficiaries. This Agreement will be binding upon and inure to the benefit of the Parties and their successors and permitted assigns. Nothing expressed or implied herein is intended or will be construed to confer upon or to give to any third party any rights or remedies by virtue hereof.

5

 

Section 2.10        Governing Law; Exclusive Jurisdiction. This Agreement is governed by and is to be construed and enforced in accordance with the laws of the State of New York without reference to the conflict of laws principles thereof. Any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by a Party or its successors or assigns, will be brought and determined exclusively in the state and federal courts located in New York. Each of the Parties hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that he or it will not bring any action relating to this Agreement in any court other than the aforesaid courts. Each of the Parties hereby irrevocably waives, and agrees not to assert in any action or proceeding with respect to this Agreement, (a) any claim that he or it is not personally subject to the jurisdiction of the above-named courts for any reason, (b) any claim that he or it or his or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted by applicable legal requirements, any claim that (1) the suit, action or proceeding in such court is brought in an inconvenient forum, (2) the venue of such suit, action or proceeding is improper or (3) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

Section 2.11        Counterparts. This Agreement may be executed in one or more counterparts each of which when so executed and delivered will be deemed an original but all of which will constitute one and the same Agreement (including by means of electronic delivery).

[Signature Pages Follow]

6

 

The Seller and each party listed on Exhibit A hereto have caused this Stock Purchase to be duly executed as of the date first above written.

 

  SELLER
     
   
     
     
  /s/ Robert Duggan
 
 

Robert Duggan

 

Address: Robert Duggan

c/o Duggan Investments

616 Druid Road East

Clearwater, FL 33756

 

 

 

 

 

[Signature Page to Stock Purchase Agreement]

 

 

  BUYERS:
   
  MAHKAM ZANGANEH REVOCABLE TRUST
  SHAUN ZANGANEH IRREVOCABLE TRUST
   
  By:

/s/ Mahkam Zanganeh

    Name: Mahkam Zanganeh
    Title: Trustee

 

 

 

 

[Signature Page to Stock Purchase Agreement] 

 

 

Exhibit A

Buyer Number of ADS Shares Purchased Purchase Price ($USD)

Mahkam Zanganeh Revocable Trust

51 Adam Way

Atherton, CA 94027

2,104,541 2,999,999.41

Shaun Zanganeh Irrevocable Trust

51 Adam Way

Atherton, CA 94027

2,104,541 2,999,999.41
Total 4,209,082 $5,999,998.82

 

EX-99.5 3 ex995to13d11732sum_01232020.htm JOINT FILING AGREEMENT

Exhibit 99.5

 

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Ordinary Shares, par value £0.01 per share, of Summit Therapeutics PLC, a foreign private issuer incorporated in England and Wales. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. 

 

 

/s/ Mahkam Zanganeh

  Mahkam Zanganeh
   
   
  MAHKAM ZANGANEH REVOCABLE TRUST
  SHAUN ZANGANEH IRREVOCABLE TRUST
   
  By:

/s/ Mahkam Zanganeh

    Name: Mahkam Zanganeh
    Title: Trustee